Kadimastem is a regenerative medicine company focused on industrial development and commercialization of stem cell-based therapeutics. Kadimastem's proprietary technologies enable differentiation of pluripotent stem cells into either insulin-secreting beta cells, or neuro-glial cells (including astrocytes and oligodendrocytes). Based on its differentiation technologies, Kadimastem is advancing two therapeutic programs. In diabetes, islet cells derived from large-scale stem cell cultures will be implanted to patients to restore glucose control without need for insulin injections. In the neurodegenerative disease ALS, stem cell-derived astrocytes will be injected in the cerebrospinal fluid reducing motoneuron death, slowing disease progression.
Business Development Executive, Nature Publishing Group, Springer Nature
Sales Account Executive, Springer Nature
Managing Director, Thoroughly Good Consulting